Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc., a prominent player in the life sciences sector, is revolutionizing the field of proteomics. The company is known for its development and commercialization of the Proteograph Product Suite, an integrated solution designed to unlock deep, unbiased biological information. The suite comprises consumables, automation instrumentation, and software that enable comprehensive proteomic profiling and sample analysis, providing researchers with a detailed view of the proteome.
Seer's technology is built around proprietary engineered nanoparticles, which offer unmatched depth and scale in proteomic studies. This innovative approach allows for the detection of over 6,000 proteins and more than 55,000 peptide IDs in complex samples, such as plasma. The Proteograph Product Suite is designed for ease of use, with features like minimal hands-on time and fully automated workflows, making it accessible to a wide range of research labs.
The company primarily targets academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies, offering its products for non-diagnostic and non-clinical purposes. Seer has established significant collaborations with industry leaders like Discovery Life Sciences, Bruker Scientific LLC, and Thermo Electron North America LLC, enhancing its market reach and technological capabilities.
Recently, Seer has made headlines through its partnership with Panome Bio to integrate deep, unbiased proteomics with metabolomics, aiming to accelerate research in biomarker discovery and drug development. The collaboration is expected to facilitate groundbreaking studies with robust pathway analyses, significantly advancing the understanding of biology and disease.
In another noteworthy development, Seer announced a major study published in Nature Communications, conducted in collaboration with Weill Cornell Medicine. This research showcased Seer's Proteograph workflow's potential to unveil novel proteogenomic insights, linking genetic variation with protein abundance at peptide level resolution. This study is a testament to Seer's commitment to advancing multi-omics research and enhancing precision medicine.
Seer's financial outlook remains optimistic despite macroeconomic challenges. The company continues to drive the adoption of its Proteograph Product Suite by expanding its Technology Access Center and increasing its commercial reach. As more customer data and third-party publications highlight the power of Seer's technology, the company anticipates growing adoption and impact in the scientific community.
In summary, Seer, Inc. is at the forefront of proteomics, offering transformative solutions that provide unparalleled insights into the proteome, thus paving the way for significant advancements in biological research and precision medicine.
Seer (Nasdaq: SEER) has been ranked No. 57 on the 2024 Deloitte Technology Fast 500™, achieving a remarkable 2,440% revenue growth. The company attributes this growth to increased adoption of its Proteograph Product Suite and customer discoveries across neurodegenerative disease, cancer, and metabolic disease. Key achievements include launching a technology access center in Europe, platform usage on the SpaceX Inspiration4 mission, and establishing a co-marketing agreement with Thermo Fisher Scientific. This marks Seer's second consecutive appearance on the list, improving from their No. 5 ranking in 2023.
Seer (Nasdaq: SEER) has announced its participation in two upcoming investor conferences in November. The company will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference in Boston on November 11th at 11:30 a.m. ET, and at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21st at 10:00 a.m. ET.
Both sessions will be available via live webcast on the Investor section of Seer's website at investor.seer.bio, with archived replays accessible after the events.
Seer (NASDAQ: SEER) reported Q3 2024 financial results with revenue of $4.0 million, a 3% decrease from the prior year. Product revenue was $3.1 million, while service revenue reached $847 thousand. The company posted a gross margin of 48% and a net loss of $21.3 million. Operating expenses decreased 6% to $26.3 million. Key developments include a co-marketing agreement with Thermo Fisher Scientific, multiple research presentations at HUPO World Congress, and a $10.0 million investment in PrognomiQ. The company maintains its 2024 revenue guidance of $13-15 million and ended the quarter with $312 million in cash and investments.
Seer has announced a co-marketing and sales agreement with Thermo Fisher Scientific to jointly promote Seer's Proteograph™ Product Suite alongside Thermo Scientific Orbitrap Astral™ mass spectrometers. Under this non-exclusive agreement, Thermo Fisher's global sales force will be able to quote and sell Seer's Proteograph Product Suite starting in early 2025. The collaboration includes joint marketing activities and research studies to showcase their integrated proteomic platforms. The partnership aims to provide researchers with an integrated solution for deep, rapid, and unbiased proteomic analysis at scale.
Seer will showcase its Proteograph Product Suite at the American Society of Human Genetics (ASHG) 2024 Annual Meeting, demonstrating how deep proteomics enhances genomic research. The company will present breakthrough research in lung cancer and Alzheimer's Disease through a CoLab session featuring PrognomiQ and Salk Institute.
Key highlights include PrognomiQ's MOSAIC study, which combines proteomics with other molecular data to improve early-stage lung cancer detection, and Salk Institute's research on Relative Energy Deficiency in Sport (REDs) affecting 40% of athletes. The presentations will demonstrate how Seer's technology enables multi-omic research at unprecedented depth, scale, and speed.
Seer, Inc. (Nasdaq: SEER), a prominent life sciences company focusing on proteomics, has announced its plans to release third quarter 2024 financial results on Wednesday, November 6, 2024. The company will host a conference call and webcast to discuss the results, starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
Investors and interested parties can access the live audio webcast through the Investor section of Seer's website at investor.seer.bio. For those unable to attend the live event, an archived replay will be made available on the company's website following the presentation.
Seer, a pioneering life sciences company focused on proteomics, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management team is set to engage in a fireside chat on Thursday, September 5th at 4:05 p.m. Eastern Time. This event presents an opportunity for investors and industry professionals to gain insights into Seer's innovative platform and business strategies.
Interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. For those unable to attend in real-time, an archived replay will be made available on the company's website after the conference concludes. This participation underscores Seer's commitment to engaging with the investment community and showcasing its advancements in the proteomics field.
Seer, Inc. (Nasdaq: SEER), a leading life sciences company, has appointed Dr. Nicolas Roelofs to its Board of Directors. Dr. Roelofs brings over 35 years of operational and advisory experience in healthcare, life science tools, and diagnostics companies. His extensive background includes serving as President of the Life Sciences Group at Agilent Technologies and holding leadership positions at Bio-Rad Inc. and Stratagene Inc.
Dr. Roelofs expressed excitement about working with Seer, highlighting the company's unique capability to enable deep, unbiased proteomic analysis at unprecedented scale, speed, and robustness. He aims to leverage his industry experience to accelerate the adoption of Seer's Proteograph Product Suite and advance proteomics research.
Seer, a pioneering life sciences company focused on proteomics, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston, MA. The company's management team is set to engage in a fireside chat on Wednesday, August 14th at 3:00 p.m. Eastern Time.
Investors and interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. For those unable to attend in real-time, an archived replay will be made available on the company's website following the conference, ensuring widespread access to this important corporate update.
Seer Inc. (Nasdaq: SEER) reported its Q2 2024 financial results, highlighting a revenue of $3.1 million, a 23% decrease from the previous year. The company launched its Seer Technology Access Center (STAC) in Europe and published customer papers in Nature journals. Despite macroeconomic challenges, Seer expanded its commercial team and focused on reducing barriers to its proteomics technology. Key financials include:
- Gross profit: $1.7 million with a 56% margin
- Operating expenses: $28.8 million, down 5% year-over-year
- Net loss: $22.9 million
- Cash, equivalents, and investments: $344.6 million
Seer revised its 2024 revenue guidance to $13-$15 million, down from the previous $16-$18 million range.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
What is Seer, Inc. known for?
What does the Proteograph Product Suite include?
Who are Seer's primary customers?
What recent collaborations has Seer announced?
What are the benefits of Seer's proprietary engineered nanoparticles?
What was the focus of Seer's recent study published in Nature Communications?
What is Seer's strategy to drive adoption of its technology?
Is the Proteograph Product Suite intended for diagnostic use?
Where is Seer, Inc. headquartered?
What potential does Seer see in its technology?
